Brokerages Set Eli Lilly and Company (NYSE:LLY) Price Target at $1,141.73

Eli Lilly and Company (NYSE:LLY) has received a consensus recommendation of “Moderate Buy” from the twenty-six brokerages that are presently covering the company, MarketBeat reports. Five investment analysts have rated the stock with a hold recommendation, seventeen have assigned a buy recommendation and four have assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $1,155.3636.

A number of research firms have commented on LLY. Leerink Partnrs raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Monday, November 10th. Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. Wolfe Research boosted their target price on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a research note on Wednesday, December 3rd. Truist Financial lifted their price target on shares of Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the company a “buy” rating in a report on Wednesday, November 19th. Finally, The Goldman Sachs Group increased their price objective on shares of Eli Lilly and Company from $951.00 to $1,145.00 and gave the stock a “buy” rating in a research note on Monday, December 15th.

Eli Lilly and Company Trading Up 0.3%

Shares of LLY opened at $1,074.58 on Wednesday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,111.99. The stock’s 50-day moving average is $971.08 and its two-hundred day moving average is $835.68. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The stock has a market cap of $1.02 trillion, a PE ratio of 52.71, a P/E/G ratio of 1.09 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.Eli Lilly and Company’s revenue for the quarter was up 53.9% on a year-over-year basis. During the same period in the previous year, the company posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be paid a $1.73 dividend. The ex-dividend date is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Wealth Preservation Advisors LLC acquired a new position in shares of Eli Lilly and Company in the 1st quarter worth approximately $27,000. Sumitomo Mitsui Financial Group Inc. bought a new position in shares of Eli Lilly and Company in the second quarter valued at $27,000. Vermillion & White Wealth Management Group LLC lifted its position in shares of Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after acquiring an additional 16 shares during the last quarter. Evolution Wealth Management Inc. acquired a new position in shares of Eli Lilly and Company in the 2nd quarter worth $29,000. Finally, Steph & Co. raised its position in shares of Eli Lilly and Company by 290.0% during the third quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after purchasing an additional 29 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly released encouraging breast‑cancer data that could expand its clinical franchise and support near‑term pipeline value. Read More.
• Positive Sentiment: Company data on orforglipron (oral GLP‑1) and strong retatrutide weight‑loss results underpin a bullish 2026 outlook — these programs are potential multi‑year revenue drivers if approved and tolerability issues are managed. Read More.
• Positive Sentiment: Zacks and other analysts have lifted near‑term EPS estimates for Lilly, signaling improved earnings visibility that can support the stock once market focus shifts back to fundamentals. Read More.
• Positive Sentiment: Analysts and commentators name LLY a top stock‑split candidate for 2026 — a split could boost retail demand and liquidity if announced. Read More.
• Neutral Sentiment: Macro/flow support from a sector rotation into healthcare is lifting attention on large pharma names like Lilly, a structural tailwind but less likely to move the stock without fresh company news. Read More.
• Negative Sentiment: Major near‑term headwind: Novo Nordisk won FDA approval for an oral Wegovy pill, giving it a first‑mover advantage in the oral obesity market and pressuring Lilly’s market share expectations for oral GLP‑1 therapy. Read More.
• Negative Sentiment: Market reaction: multiple outlets note Lilly shares have pulled back as investors reassess competitive risk from Novo’s pill, and as U.S./India market dynamics intensify. Read More.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.